Reports Q3 revenue $5.115M, consensus $6.21M. Paula Brown Stafford, President and Chief Executive Officer of Novan commented, "In the third quarter, we were able to achieve a number of our internal goals, as we retired the remaining debt on the note related to our acquisition of EPI Health; we progressed as planned toward a year-end submission of the NDA for berdazimer gel, 10.3%; and we delivered year-on-year growth across our promoted products. We believe we are primed for an exciting fourth quarter as we continue to prepare for our first NDA submission, finalize our license agreement with Sato to potentially market Rhofade in Japan and work to continue our commercial product prescription growth trajectory."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NOVN:
- Jefferies Euro pharmaceutical analyst to hold analyst/industry conference call
- Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
- EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
- EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
- Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
